about
Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier SystemKidney-specific Sonoporation-mediated Gene Transfer.Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease.siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNAPodocyte biology for the bedsideNovel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Drug discovery in focal and segmental glomerulosclerosissiRNA technology in kidney transplantation: current status and future potential.Transcription factors and epigenetic modulation: its therapeutic implication in chronic kidney disease.Diverse origins of the myofibroblast—implications for kidney fibrosis.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown.Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies.A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.
P2860
Q28548472-8F6D4E50-A55B-40F8-AB39-D23AECBAE409Q30389264-14A0CD5B-454B-454A-A9D6-2E49AF3B6340Q34080235-A55ACCCA-12FF-46B0-88FF-0051DDBBD420Q34993566-682FEB21-18F9-424B-9458-4BC3054EF58AQ35224125-6A5438CB-7C10-4576-A60F-24C7FD071D67Q35256633-8B7D41D4-2A59-433D-BD3B-93D888313172Q35953867-5CF11005-F6A3-4FB2-BF77-B6DA119142A9Q36924116-B6385227-7C8F-4FC5-833D-1580C4AD801AQ38191482-2616089C-3D9A-4F98-96D9-BE939F9ED84CQ38287288-BC5CBD76-7672-4B05-A394-18C1B7DA68FDQ38316792-493AFF4C-CC0E-4B89-8CF7-29EF8DF5E804Q38458152-3B3DEF36-704F-4213-98E2-D1AE1513555FQ38814625-B7B22E4F-0872-486D-B0CF-B3F4E4270D5DQ38844709-EE985825-04F2-44C3-A8A8-9A87422D24B0Q39014347-211C98FF-37E9-4BD1-BEF4-6EB8EC50AAE3Q39038930-0FD8DF98-36D2-4F51-B08E-F4800336289DQ40734548-4DFC6B83-A345-411D-8DE6-7022D77E6A12
P2860
description
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2010)
@fr
artículu científicu espublizáu en 2010
@ast
im Januar 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2010)
@en
vědecký článek publikovaný v roce 2010
@cs
wetenschappelijk artikel (gepubliceerd op 2010)
@nl
наукова стаття, опублікована у 2010
@uk
مقالة علمية (نشرت عام 2010)
@ar
name
Novel siRNA delivery system to target podocytes in vivo
@ast
Novel siRNA delivery system to target podocytes in vivo
@en
Novel siRNA delivery system to target podocytes in vivo
@nl
type
label
Novel siRNA delivery system to target podocytes in vivo
@ast
Novel siRNA delivery system to target podocytes in vivo
@en
Novel siRNA delivery system to target podocytes in vivo
@nl
prefLabel
Novel siRNA delivery system to target podocytes in vivo
@ast
Novel siRNA delivery system to target podocytes in vivo
@en
Novel siRNA delivery system to target podocytes in vivo
@nl
P2093
P2860
P1433
P1476
Novel siRNA delivery system to target podocytes in vivo
@en
P2093
Charles E Alpers
Cora Kaiser
Jeffrey W Pippin
Jochen Reiser
Kelly L Hudkins
Paul T Brinkkoetter
Peter V Hauser
Ronald D Krofft
Stuart J Shankland
P2860
P356
10.1371/JOURNAL.PONE.0009463
P407
P577
2010-01-01T00:00:00Z